RMD STOCK ANALYSIS

ResMed Inc — price, returns and risk statistics

RMDResMed Inc

🇺🇸 USA · US · Healthcare · Medical Instruments & Supplies

Value itDuel

Price summary

Last Close

209.63 $

Jul 2, 26

Market Cap

30.8 B $

Q1 2026 (TTM)

52-Week Range

182.82 $291.49 $

Return and risk cards

Total Return

%-17.3

Trailing 1-year performance

Volatility

%25.2

Price fluctuation measure

Sharpe Ratio

-2.21

Risk/Return ratio

Sortino Ratio

-2.04

Downside risk/return

Distance to Peak

%-28.1

Difference from 52-week peak

Maximum Drawdown

-%37.3

Deepest 1-year decline

Seasonality

Seasonality Chart

Year 2023
Year 2024
Year 2025
Current Period 2026
3/3 positive months

Periodic Returns

1M

+14.7%

3M

-6.2%

6M

-12.5%

YTD

-12.5%

1Y

-17.3%

3Y

+0.6%

Returns are computed from split-adjusted closes; dividends are not included.

YTD Return — Stock vs Asset Classes

Year-to-date
RMD-12.5%Gold-3.2%Silver-10.4%S&P 500+9.3%

Stock and gold/silver returns are in USD (metals converted into the stock's currency). The S&P 500 index is measured in its own currency.

Monthly positivity

Monthly Avg Positive/Negative Close

Positive Count
Negative Count
Average Positive %
Average Negative %

Frequently Asked Questions

What is the current ResMed Inc (RMD) stock price?

RMD last closed at 209.63 $ (Jul 2, 26). Price data is refreshed after every trading day.

What is the P/E ratio of RMD?

ResMed Inc trades at a trailing-twelve-month P/E of 20.28. See the comparison tables on the Peers tab for the industry context.

What is the market capitalization of ResMed Inc?

ResMed Inc (RMD) has a market capitalization of approximately 30.8 B $ as of the latest reported period.

Who are the main competitors of RMD?

Key peers of ResMed Inc include Resmed Inc, Fisher & Paykel Healthcare Corporation Ltd, EssilorLuxottica S. A., Ansell Ltd. A detailed metric comparison is available on the Peers tab.

Go deeper on RMD

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.